Becton Dickinson & Co. (BDX)

Name: Becton Dickinson & Co. (BDX): results, filings decoded, planned insider sales, 13F holders, insiders, Congress and short interest
Creator: GreekSoup
License: https://creativecommons.org/licenses/by/4.0/

Compare with another name

Becton Dickinson & Co. (BDX) reported revenue of $5.0 billion for Q3 FY2026, the quarter ended 30 June 2026, down 9.5% on the same quarter a year earlier. Net income was $377 million, down 34.3% on the year, and diluted earnings per share $1.37. The figures are the company's own, from the 10-Q it filed with the SEC on 6 August 2026.

Revenue$5.0 billiondown 9.5%

Net income$377 milliondown 34.3%

Diluted EPS$1.37

QuarterQ3 FY2026ended 30 June 2026

Ratios

From the filings

ROE3.9%

ROCE5.3%

Operating margin9.6%

Net margin4.5%

FCF marginn/a

Interest cover3.41

Debt to equity0.55

Cash conversionn/a

Share count, 1 year-5.0%

Sales CAGR, 3 years5.0%

Profit CAGR, 3 years-1.9%

EPS, TTM$3.31

At the close of 21 September 2026

Price$180.70

Market cap$49.2 billion

Stock P/E54.59

Price to book2.02

EV / EBITDA13.91

Dividend yield2.3%

Market cap / sales2.36

52-week high$210.02

52-week low$140.71

Price, 1 year-3.4%

Price CAGR, 3 years-12.0%

Price CAGR, 5 years-6.8%

Every figure is arithmetic on the filed lines (hover a name for the formula); the priced ones use the latest daily close, CBOE delayed quotes, daily history, by CBOE, for splits. Debt to equity here stands on long-term debt as Becton Dickinson & Co. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.

Price, 17 September 2021 to 21 September 2026

Show

50-day average 200-day average Volume

Daily closes from CBOE delayed quotes, daily history, by CBOE, for splits; the last is 21 September 2026. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Drawn in your browser; the range and overlay you pick are remembered here only.

The public record on BDX

Filings	35 in twelve months: 22 current reports (8-K), about 8 officer or director change; 7 regulation fd disclosure; 6 results of operations; 4 other events; 2 material agreement
Planned insider sales	26 Form 144 notices in twelve months, $8.1 million; latest 26 August 2026
Options tape	put/call 0.71 by open interest on 23 September 2026; the straddle prices a 5.5% move to 16 October 2026
Holders	8 of the followed funds hold it; largest Geode Capital Management; 7 Schedule 13D or 13G filings in twelve months
Insider trading	19 sales and 0 purchases on Form 4 in twelve months
Congress	2 House trades disclosed in six months
Short interest	10.7 million shares short, 6.12 days to cover at 31 August 2026
Documents	the 10-K, the 10-Qs, the proxy and 6 earnings press releases, each linked

Quarterly results, the last 12 quarters

	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	5,087	4,706	5,045	4,990	5,437	5,168	5,272	5,509	5,891	5,252	4,714	4,983
Cost of revenue	3,385	2,679	2,741	2,683	2,950	2,933	3,015	2,875	3,092	2,841	2,560	2,668
Gross profit	1,702	2,027	2,304	2,307	2,487	2,235	2,257	2,634	2,799	2,411	2,154	2,315
Gross margin	33%	43%	46%	46%	46%	43%	43%	48%	48%	46%	46%	46%
R&D	281	290	299	299	302	343	302	297	323	306	249	258
SG&A	1,137	1,213	1,193	1,196	1,255	1,318	1,273	1,320	1,367	1,393	1,213	1,261
Operating income	349	439	734	602	622	453	546	882	698	552	93.0	663
Operating margin	7%	9%	15%	12%	11%	9%	10%	16%	12%	11%	2%	13%
Interest expense	113	111	125	137	155	155	151	152	155	153	149	132
Pre-tax income	181	359	633	500	513	306	363	703	509	393	39.0	554
Tax rate	15%	21%	15%	3%	22%	1%	15%	18%	3%	3%	195%	18%
Net income	108	281	537	487	400	303	308	574	493	382	-311	377
Net margin	2%	6%	11%	10%	7%	6%	6%	10%	8%	7%	-7%	8%
Diluted EPS	$0.35	$0.96	$1.85	$1.68	$1.37	$1.04	$1.07	$2.00	$1.71	$1.34	-$1.11	$1.37
Operating cash flow	n/a	n/a	n/a	n/a	n/a	693	n/a	n/a	n/a	657	n/a	n/a
Capital expenditure	294	116	134	179	296	105	129	174	352	108	125	143
Free cash flow	n/a	n/a	n/a	n/a	n/a	588	n/a	n/a	n/a	549	n/a	n/a
Buybacks	0.0	500	0.0	0.0	0.0	750	0.0	0.0	250	250	2,000	0.0
Dividends paid	265	275	275	275	275	302	298	299	297	299	290	286
Shares outstanding	290m	289m	289m	289m	289m	287m	287m	287m	285m	285m	276m	272m
Filing	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Profit and loss, 12 fiscal years and the trailing twelve months

	FY2014 †	FY2015 †	FY2016	FY2017 †	FY2018 †	FY2019	FY2020 †	FY2021 †	FY2022	FY2023	FY2024	FY2025	TTM
Revenue	8,446	10,282	12,483	12,093	15,983	17,290	16,074	19,131	18,870	19,372	20,178	21,840	20,840
Cost of revenue	4,145	5,587	6,492	6,128	8,721	9,002	9,276	10,500	10,393	11,202	11,053	11,915	11,161
Gross profit	4,301	4,695	5,991	5,942	7,262	8,288	7,577	9,427	8,477	8,170	9,125	9,925	9,679
Gross margin	50.9%	45.7%	48.0%	49.1%	45.4%	47.9%	47.1%	49.3%	44.9%	42.2%	45.2%	45.4%	46.4%
Research and development	550	632	828	770	1,006	1,062	1,039	1,279	1,256	1,237	1,190	1,265	1,136
Selling, general and administrative	2,145	2,563	3,005	2,909	4,015	4,332	4,185	4,719	4,709	4,719	4,857	5,278	5,234
Operating income	1,606	1,074	1,430	1,522	1,509	1,760	912	2,250	2,282	2,111	2,397	2,579	2,006
Operating margin	19.0%	10.4%	11.5%	12.6%	9.4%	10.2%	5.7%	11.8%	12.1%	10.9%	11.9%	11.8%	9.6%
Interest expense	135	371	388	521	706	639	528	469	398	452	528	613	589
Pre-tax income	1,522	739	1,074	976	1,173	1,176	414	1,692	1,783	1,662	2,005	1,881	1,495
Income tax	337	44.0	97.0	-124	862	-57.0	62.0	88.0	148	132	300	203	205
Effective tax rate	22.1%	6.0%	9.0%	-12.7%	73.5%	-4.8%	15.0%	5.2%	8.3%	7.9%	15.0%	10.8%	13.7%
Net income	1,185	695	976	1,100	311	1,233	874	2,092	1,779	1,484	1,705	1,678	941
Net margin	14.0%	6.8%	7.8%	9.1%	1.9%	7.1%	5.4%	10.9%	9.4%	7.7%	8.4%	7.7%	4.5%
Diluted EPS	$5.99	$3.35	$4.49	$4.60	$0.60	$3.94	$2.71	$6.85	$5.88	$4.94	$5.86	$5.82	$3.31
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Income statement lines from each year's 10-K, the year linked to its filing; TTM is the sum of the last four quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

	FY2014 †	FY2015 †	FY2016	FY2017 †	FY2018 †	FY2019	FY2020 †	FY2021 †	FY2022	FY2023	FY2024	FY2025	TTM
Operating cash flow	1,746	1,730	2,559	2,550	2,865	3,330	3,539	4,647	n/a	n/a	n/a	n/a	n/a
Capital expenditure	592	596	693	727	895	957	769	1,194	973	874	725	760	728
Free cash flow	1,154	1,134	1,866	1,823	1,970	2,373	2,770	3,453	n/a	n/a	n/a	n/a	n/a
Free cash flow margin	13.7%	11.0%	14.9%	15.1%	12.3%	13.7%	17.2%	18.0%	n/a	n/a	n/a	n/a	n/a
Depreciation and amortisation	562	891	1,114	1,088	1,978	2,253	2,115	2,230	2,229	2,288	2,286	2,462	2,454
Share-based compensation	113	166	196	174	322	261	236	229	233	259	247	258	259
Buybacks	400	0.0	0.0	220	0.0	0.0	0.0	1,750	500	0.0	500	1,000	2,500
Dividends paid	421	485	562	677	927	984	1,026	1,048	1,082	1,114	1,100	1,196	1,172
Dividend per share	$2.18	$2.40	$2.64	$2.92	$3.00	$3.08	$3.16	$3.32	$3.48	$3.64	$3.80	$4.16	n/a
Diluted shares, weighted	198m	208m	218m	224m	265m	275m	282m	292m	287m	288m	291m	289m	275m
Shares outstanding at period end	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	272m
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Buybacks and dividends are the cash paid in the year, from the cash flow statement; the dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet at year end

	FY2014 †	FY2015 †	FY2016	FY2017 †	FY2018 †	FY2019	FY2020 †	FY2021 †	FY2022	FY2023	FY2024	FY2025	TTM
Total assets	12,384	26,478	25,586	37,734	53,904	51,765	54,012	53,866	52,934	52,780	57,286	55,325	50,731
Cash and equivalents	1,861	1,424	1,541	14,179	1,140	536	2,825	2,283	1,006	1,416	1,717	641	708
Receivables	1,187	1,618	1,618	1,744	2,319	2,345	2,398	2,350	2,191	2,534	3,033	2,994	2,364
Inventory	1,495	1,959	1,719	1,818	2,451	2,579	2,743	2,743	3,224	3,273	3,843	3,894	3,316
Goodwill	1,090	7,537	7,419	7,563	23,600	23,376	23,620	23,901	24,621	24,522	26,465	26,612	25,944
Long-term debt	3,768	11,370	10,550	18,667	18,894	18,081	17,224	17,110	13,886	14,738	17,940	17,621	13,511
Operating lease liabilities	n/a	n/a	n/a	n/a	n/a	n/a	336	344	384	414	667	704	n/a
Shareholders' equity	5,053	7,164	7,633	12,948	20,994	21,081	23,765	23,677	25,282	25,796	25,890	25,390	24,416
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

At the fiscal year end; the TTM column is the latest quarter end. A line the company does not tag under the usual name is left out.

Compounded growth

	10 years	5 years	3 years	TTM
Sales growth, compounded	7.8%	6.3%	5.0%	-2.6%
Profit growth, compounded	9.2%	13.9%	-1.9%	-40.6%
Return on equity, average	6.7%	7.0%	6.3%	6.6%

Compounded growth is the latest fiscal year over the year that many years earlier, annualised; the TTM column is the last four quarters over the four before. Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Peers: Surgical & Medical Instruments & Apparatus

Company	Market cap	P/E	ROE	Op. margin	Sales growth TTM	Debt to equity	Div. yield
Stryker Corp. SYK	$105.2 billion	28.41	15.5%	21.4%	8.5%	0.62	1.3%
3M Co. MMM	$85.1 billion	29.30	101.5%	18.4%	2.3%	3.69	1.8%
Boston Scientific Corp. BSX	$63.4 billion	17.70	14.7%	19.8%	13.5%	0.44	n/a
Becton Dickinson & Co. BDX	$49.2 billion	54.59	3.9%	9.6%	-2.6%	0.55	2.3%
Dexcom Inc. DXCM	$33.7 billion	35.38	38.1%	22.9%	15.5%	0.03	n/a
Resmed Inc. RMD	$32.3 billion	21.44	23.1%	33.4%	9.9%	0.10	1.1%
West Pharmaceutical Services Inc. WST	$25.5 billion	46.32	18.9%	20.5%	12.4%	0.07	0.2%
Solventum Corp. SOLV	$15.1 billion	10.85	29.9%	25.0%	-0.9%	1.06	n/a
Baxter International Inc. BAX	$11.9 billion	n/a	-17.1%	-2.4%	5.4%	1.54	2.3%
Insulet Corp. PODD	$9.7 billion	26.37	26.4%	16.9%	29.4%	0.65	n/a

The names on this site in the same industry (the SEC's SIC description), by market capitalisation. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close.

Filings

Filing	Period	Filed	Where
10-Q	30 June 2026	6 August 2026	EDGAR
10-Q	31 March 2026	7 May 2026	EDGAR
10-Q	31 December 2025	9 February 2026	EDGAR
10-K	30 September 2025	25 November 2025	EDGAR
10-Q	30 June 2025	7 August 2025	EDGAR
10-Q	31 March 2025	1 May 2025	EDGAR
10-Q	31 December 2024	6 February 2025	EDGAR
10-K	30 September 2024	27 November 2024	EDGAR
10-Q	30 June 2024	1 August 2024	EDGAR
10-Q	31 March 2024	2 May 2024	EDGAR

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install